Faron Pharmaceuticals Oy (LSE:FARN) FFO


LSE:FARN Faron Pharmaceuticals Oy LSE:FARN
22 GF Score
Price £0.41
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy FFO?

FFO (Funds from operations) only applies to REITs.

LSE:FARN
22GF Score
Faron Pharmaceuticals Oy LSE:FARN
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARON:Finland4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
22GF Score

Get the complete analysis for LSE:FARN

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.41
Price